lifestyle, or concomitant medications that might affect SU levels, and for which the Patient Panel requested guidance. The Voting Panel aimed to provide guidance without implying any "patient-blaming" for the manifestations of gout given its strong genetic determinants. Indications for ULT are expanded from the 2012 ACR Guidelines for the Management of Gout, but consistent with the 2016 update of the EULAR gout recommendations This updated guideline effort also identifies several areas that